Website News and Research

RSS

Hutchinson Technology commences tender/exchange offer of 3.25% Convertible Subordinated Notes

Hutchinson Technology Incorporated today announced that it has commenced an offer to exchange or purchase, at the election of each holder and subject to the limitations described below, up to $75,294,000 of its 3.25% Convertible Subordinated Notes due 2026 (the "Old Notes").

10 Jan 2011

SonoSite fourth quarter revenue increases 27% to $89 million

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced preliminary revenue results for the fourth quarter and year ended December 31, 2010.

10 Jan 2011

Pennsaid fourth quarter prescriptions increase 20% sequentially

Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

10 Jan 2011

Hospice of Michigan offers toolkit to help people on end-of-life decision making and planning

Hospice of Michigan offers a complete toolkit to empower individuals and families to take control of end-of-life decision making and planning. The free resource is the www.haveyouhadthetalk.org website from which a toolkit can be downloaded and printed for free.

10 Jan 2011

FDA warns retailers for illegal sale of tobacco products to minors

The U.S. Food and Drug Administration today announced it is issuing its first warning letters to retailers for the illegal sale of tobacco products to minors in violation of the 2009 Family Smoking Prevention and Tobacco Control Act.

10 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

Underwriters exercise over-allotment option in Amarin ADS public offering

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 1,800,000 additional ADSs to cover over-allotments.

7 Jan 2011

StemCells $10 million common stock offering to close today

StemCells, Inc. announced today that it has entered into an agreement to sell ten million shares of its common stock to selected institutional investors at a price of $1.00 per share, which represents a 10% discount to the closing price per share of January 6. The offering is expected to close today, subject to customary closing conditions, and StemCells expects to receive net proceeds, after deducting offering expenses and fees, of approximately $9.4 million.

7 Jan 2011

Elevated rates of 'Sarcoid Like' Granulomatous Pulmonary Disease found in WTC responders

Mount Sinai researchers coordinating the largest clinical study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in World Trade Center (WTC) responders have found that the rate of the condition was increased in this group as compared to the records of pre-9/11 FDNY personnel. The study is published online in the American Journal of Industrial Medicine.

7 Jan 2011

Viveve's non-surgical vaginal laxity treatment receives European CE mark

Viveve, Inc., a development stage women's health company, announced today that it has received the European CE (Conformite Europeenne) mark for the use of its Viveve System for the non-surgical treatment of laxity of the vaginal introitus (opening), after childbirth, to improve female sexual function.

7 Jan 2011

FDA introduces new Web resource that helps companies to save time, resources

The U.S. Food and Drug Administration today introduced a new Web resource called FDA Basics for Industry to help companies and others save time and resources in their interactions with the agency.

7 Jan 2011

Antigenics announces name change to Agenus

Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.

6 Jan 2011

Symphogen closes €100 million stock to a group of investors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors.

6 Jan 2011

MAXIMUS signs Eligibility Support Services contract with HHSC

MAXIMUS, a leading provider of government services, announced today that it has signed the previously announced Eligibility Support Services contract with the Texas Health and Human Services Commission. The three-year base contract is valued at $315.3 million with an additional two option years.

6 Jan 2011

Californians can now access information about local healthcare providers using MyHealthResource

Realizing the New Year's resolution of "good health" could be just a click of the mouse away - even for Californians without adequate health insurance, thanks to a free, online resource from Californians for Patient Care. Using MyHealthResource, available at www.calpatientcare.org, Californians can access information about local healthcare providers that provide primary, dental, vision and mental healthcare services to the uninsured and underinsured.

6 Jan 2011

Nicotine replacement therapies to quit smoking

Although smoking is an expensive habit, let's face it, nicotine replacement therapies (NRT) to help you quit smoking can seem like expensive purchases as well.

6 Jan 2011

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

5 Jan 2011

New laboratory manual on imaging in developmental biology

Imaging technologies have revolutionized the study of developmental biology and are now essential tools for researchers in the field. A newly released laboratory manual, Imaging in Developmental Biology, presents a comprehensive set of visualization methods specifically for developmental biologists. It is the newest volume in a series of imaging manuals published by Cold Spring Harbor Laboratory Press.

5 Jan 2011

Low-radiocarbon nutrition permanently reduces genetic damage to brain cells

A new method of child and maternal nutrition could prevent a specific type of genetic damage that would otherwise occur in up to 160 million brain cells in each person over their lifetime. Preventing this genetic damage could have significant implications related to aging and cancer.

5 Jan 2011

Cold Spring Harbor Protocols features organ culture methods and transcriptome analysis

New technologies and methods are spurring a renaissance in the study of organogenesis. Organogenesis, essentially the process through which a group of cells becomes a functioning organ, has important connections to biological processes at the cellular and developmental levels, and its study offers great potential for medical treatments through tissue engineering approaches.

4 Jan 2011